Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.73 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.73 |
| ▸ | LDHA | P00338 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | LDHB | P07195 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL30669516 | 1.00 | CA4 (0.73) | CA4FAHD1LDHAMEN1BLM | |
| Oxalic Acid SCHEMBL15140865 | 1.00 | CA4 (0.73) | CA4FAHD1LDHAMEN1BLM | |
| Oxalic Acid SCHEMBL12494817 | 0.96 | CA4 (0.67) | CA4FAHD1LDHAMEN1BLM | |
| Oxalic Acid SCHEMBL12495201 | 0.96 | CA4 (0.67) | CA4FAHD1LDHAMEN1BLM | |
| Oxalic Acid SCHEMBL28304437 | 0.95 | CA4 (0.64) | CA4FAHD1LDHAMEN1BLM | |
| Oxalic Acid SCHEMBL29516863 | 0.92 | CA4 (0.61) | CA4FAHD1LDHAMEN1BLM | |
| Oxalic Acid SCHEMBL29516963 | 0.92 | CA4 (0.61) | CA4FAHD1LDHAMEN1BLM | |
| Oxalic Acid SCHEMBL9657843 | 0.91 | CA4 (0.58) | CA4FAHD1LDHAMEN1BLM | |
| Oxalic Acid SCHEMBL7164653 | 0.91 | CA4 (0.58) | CA4FAHD1LDHAMEN1BLM | |
| Oxalic Acid SCHEMBL6569012 | 0.91 | CA4 (0.58) | CA4FAHD1LDHAMEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4131641-A | FROM WASTES, SLURRYING WITH NICKEL CHLORIDE, OXIDATION, HYDROGEN CHLORIDE | ROHM AND HAAS COMPANY (US) | 1978-12-26 | — | — | US | claimed |
| US-20260138079-A1 | SYSTEMS FOR REMOVING CARBON DIOXIDE FROM A CARBON DIOXIDE CONTAINING GAS, AND RELATED METHODS | Schlumberger Tech Corporation (US) | 2026-05-21 | — | — | US | disclosed |
| US-12478918-B1 | Systems for removing carbon dioxide from a carbon dioxide containing gas, and related methods | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2025-11-25 | — | — | US | disclosed |
| WO-2024206329-A1 | NUCLEIC ACID MOLECULES ENCODING BI-SPECIFIC SECRETED ENGAGERS AND USES THEREOF | MODERNATX, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024206126-A1 | CD16-BINDING ANTIBODIES AND USES THEREOF | MODERNATX, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024206209-A1 | ANTI-CD38, ANTI-BCMA, ANTI-GPRC5D, AND ANTI-FCRH5 ANTIBODIES AND USES TO TREAT VARIOUS DISEASES SUCH AS CANCER | MODERNATX, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024118866-A1 | GPC3-SPECIFIC ANTIBODIES, BINDING DOMAINS, AND RELATED PROTEINS AND USES THEREOF | MODERNATX, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024097639-A1 | HSA-BINDING ANTIBODIES AND BINDING PROTEINS AND USES THEREOF | MODERNATX, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4301859-A1 | ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Code Biotherapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-4251127-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INNER EAR DISORDERS THROUGH LOCAL ADMINISTRATION IN THE TYMPANIC AREA | Moussy, Alain (FR) | 2023-10-04 | — | — | EP | disclosed |
| WO-2022187586-A1 | ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | CODE BIOTHERAPEUTICS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022112511-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INNER EAR DISORDERS THROUGH LOCAL ADMINISTRATION IN THE TYMPANIC AREA | MOUSSY ALAIN (FR) | 2022-06-02 | — | — | WO | disclosed |
| EP-3959233-A1 | NETRIN G1 AND NETRIN G1 LIGAND PEPTIDES AND ANTIBODIES AND USES THEREOF | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20210177788-A1 | BROAD SPECTRUM PHARMACOLOGICAL COMPOSITION FOR TREATMENT OF VARIOUS INFECTIONS AND DISEASES AND METHODS OF USE | GREYFER INNOVA PHARMA, LLC (PK) | 2021-06-17 | — | — | US | disclosed |
| CN-101200755-A | Bacterium identification reagent kit as well as preparation method and uses thereof | UNIV SOUTH CHINA AGRICULT (CN) | 2008-06-18 | — | — | CN | disclosed |
| EP-1011346-B1 | ANIMAL FEED CONTAINING CARBOXYLIC ACIDS | WISCONSIN ALUMNI RES FOUND (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1011346-A1 | ANIMAL FEED CONTAINING CARBOXYLIC ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-06-28 | — | — | EP | disclosed |
| US-6022555-A | ENHANCING PHOSPHORUS UTILIZATION IN FOWL BY FEEDING A FEED ADDITIVE CONTAINING A TRICARBOXYLIC ACID IN GIVEN DRY WEIGHT TO IMPROVE BIOAVAILABILITY OF PHOSPHORUS IN FEED | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-02-08 | — | — | US | disclosed |
| WO-1999012431-A1 | ANIMAL FEED CONTAINING CARBOXYLIC ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-03-18 | — | — | WO | disclosed |
| US-4131641-A | FROM WASTES, SLURRYING WITH NICKEL CHLORIDE, OXIDATION, HYDROGEN CHLORIDE | ROHM AND HAAS COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138079-A1 | SYSTEMS FOR REMOVING CARBON DIOXIDE FROM A CARBON DIOXIDE CONTAINING GAS, AND RELATED METHODS | CA2, FTO, CA9 | CA4 4/4885FAHD1 158/4885LDHA 197/4885 |
| US-20210177788-A1 | BROAD SPECTRUM PHARMACOLOGICAL COMPOSITION FOR TREATMENT OF VARIOUS INFECTIONS AND DISEASES AND METHODS OF USE | CS, OTC, SLC25A11 | CA4 84/4885FAHD1 303/4885LDHA 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.